1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Sickle Cell Disease Drug Revenue
1.4 Market Analysis by Type
1.4.1 Global Sickle Cell Disease Drug Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 ARQ-092
1.4.3 BIVV-003
1.4.4 CAL-H
1.4.5 CTX-001
1.4.6 DRX-194
1.4.7 Others
1.5 Market by Application
1.5.1 Global Sickle Cell Disease Drug Market Share by Application: 2021-2026
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Sickle Cell Disease Drug Market
1.8.1 Global Sickle Cell Disease Drug Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Sickle Cell Disease Drug Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Sickle Cell Disease Drug Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Sickle Cell Disease Drug Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Sickle Cell Disease Drug Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Sickle Cell Disease Drug Sales Volume Market Share by Region (2015-2020)
3.2 Global Sickle Cell Disease Drug Sales Revenue Market Share by Region (2015-2020)
3.3 North America Sickle Cell Disease Drug Sales Volume
3.3.1 North America Sickle Cell Disease Drug Sales Volume Growth Rate (2015-2020)
3.3.2 North America Sickle Cell Disease Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Sickle Cell Disease Drug Sales Volume
3.4.1 East Asia Sickle Cell Disease Drug Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Sickle Cell Disease Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Sickle Cell Disease Drug Sales Volume (2015-2020)
3.5.1 Europe Sickle Cell Disease Drug Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Sickle Cell Disease Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Sickle Cell Disease Drug Sales Volume (2015-2020)
3.6.1 South Asia Sickle Cell Disease Drug Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Sickle Cell Disease Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Sickle Cell Disease Drug Sales Volume (2015-2020)
3.7.1 Southeast Asia Sickle Cell Disease Drug Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Sickle Cell Disease Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Sickle Cell Disease Drug Sales Volume (2015-2020)
3.8.1 Middle East Sickle Cell Disease Drug Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Sickle Cell Disease Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Sickle Cell Disease Drug Sales Volume (2015-2020)
3.9.1 Africa Sickle Cell Disease Drug Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Sickle Cell Disease Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Sickle Cell Disease Drug Sales Volume (2015-2020)
3.10.1 Oceania Sickle Cell Disease Drug Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Sickle Cell Disease Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Sickle Cell Disease Drug Sales Volume (2015-2020)
3.11.1 South America Sickle Cell Disease Drug Sales Volume Growth Rate (2015-2020)
3.11.2 South America Sickle Cell Disease Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Sickle Cell Disease Drug Sales Volume (2015-2020)
3.12.1 Rest of the World Sickle Cell Disease Drug Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Sickle Cell Disease Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Sickle Cell Disease Drug Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Sickle Cell Disease Drug Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Sickle Cell Disease Drug Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Sickle Cell Disease Drug Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Sickle Cell Disease Drug Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Sickle Cell Disease Drug Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Sickle Cell Disease Drug Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Sickle Cell Disease Drug Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Sickle Cell Disease Drug Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Sickle Cell Disease Drug Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Sickle Cell Disease Drug Sales Volume Market Share by Type (2015-2020)
14.2 Global Sickle Cell Disease Drug Sales Revenue Market Share by Type (2015-2020)
14.3 Global Sickle Cell Disease Drug Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Sickle Cell Disease Drug Consumption Volume by Application (2015-2020)
15.2 Global Sickle Cell Disease Drug Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Sickle Cell Disease Drug Business
16.1 Acceleron Pharma Inc
16.1.1 Acceleron Pharma Inc Company Profile
16.1.2 Acceleron Pharma Inc Sickle Cell Disease Drug Product Specification
16.1.3 Acceleron Pharma Inc Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 bluebird bio Inc
16.2.1 bluebird bio Inc Company Profile
16.2.2 bluebird bio Inc Sickle Cell Disease Drug Product Specification
16.2.3 bluebird bio Inc Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Annexin Pharmaceuticals AB
16.3.1 Annexin Pharmaceuticals AB Company Profile
16.3.2 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Product Specification
16.3.3 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Addmedica SAS
16.4.1 Addmedica SAS Company Profile
16.4.2 Addmedica SAS Sickle Cell Disease Drug Product Specification
16.4.3 Addmedica SAS Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 Bioverativ Inc
16.5.1 Bioverativ Inc Company Profile
16.5.2 Bioverativ Inc Sickle Cell Disease Drug Product Specification
16.5.3 Bioverativ Inc Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Angiocrine Bioscience Inc
16.6.1 Angiocrine Bioscience Inc Company Profile
16.6.2 Angiocrine Bioscience Inc Sickle Cell Disease Drug Product Specification
16.6.3 Angiocrine Bioscience Inc Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 Calimmune Inc
16.7.1 Calimmune Inc Company Profile
16.7.2 Calimmune Inc Sickle Cell Disease Drug Product Specification
16.7.3 Calimmune Inc Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 Bio Products Laboratory Ltd
16.8.1 Bio Products Laboratory Ltd Company Profile
16.8.2 Bio Products Laboratory Ltd Sickle Cell Disease Drug Product Specification
16.8.3 Bio Products Laboratory Ltd Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 ArQule Inc
16.9.1 ArQule Inc Company Profile
16.9.2 ArQule Inc Sickle Cell Disease Drug Product Specification
16.9.3 ArQule Inc Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 Bristol-Myers Squibb Co
16.10.1 Bristol-Myers Squibb Co Company Profile
16.10.2 Bristol-Myers Squibb Co Sickle Cell Disease Drug Product Specification
16.10.3 Bristol-Myers Squibb Co Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.11 Errant Gene Therapeutics LLC
16.11.1 Errant Gene Therapeutics LLC Company Profile
16.11.2 Errant Gene Therapeutics LLC Sickle Cell Disease Drug Product Specification
16.11.3 Errant Gene Therapeutics LLC Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.12 Gilead Sciences Inc
16.12.1 Gilead Sciences Inc Company Profile
16.12.2 Gilead Sciences Inc Sickle Cell Disease Drug Product Specification
16.12.3 Gilead Sciences Inc Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.13 CRISPR Therapeutics
16.13.1 CRISPR Therapeutics Company Profile
16.13.2 CRISPR Therapeutics Sickle Cell Disease Drug Product Specification
16.13.3 CRISPR Therapeutics Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.14 Gamida Cell Ltd
16.14.1 Gamida Cell Ltd Company Profile
16.14.2 Gamida Cell Ltd Sickle Cell Disease Drug Product Specification
16.14.3 Gamida Cell Ltd Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.15 Editas Medicine Inc
16.15.1 Editas Medicine Inc Company Profile
16.15.2 Editas Medicine Inc Sickle Cell Disease Drug Product Specification
16.15.3 Editas Medicine Inc Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.16 CSL Ltd
16.16.1 CSL Ltd Company Profile
16.16.2 CSL Ltd Sickle Cell Disease Drug Product Specification
16.16.3 CSL Ltd Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.17 Global Blood Therapeutics Inc
16.17.1 Global Blood Therapeutics Inc Company Profile
16.17.2 Global Blood Therapeutics Inc Sickle Cell Disease Drug Product Specification
16.17.3 Global Blood Therapeutics Inc Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.18 Genethon SA
16.18.1 Genethon SA Company Profile
16.18.2 Genethon SA Sickle Cell Disease Drug Product Specification
16.18.3 Genethon SA Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.19 Daiichi Sankyo Co Ltd
16.19.1 Daiichi Sankyo Co Ltd Company Profile
16.19.2 Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Product Specification
16.19.3 Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Sickle Cell Disease Drug Manufacturing Cost Analysis
17.1 Sickle Cell Disease Drug Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Sickle Cell Disease Drug
17.4 Sickle Cell Disease Drug Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Sickle Cell Disease Drug Distributors List
18.3 Sickle Cell Disease Drug Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Sickle Cell Disease Drug (2021-2026)
20.2 Global Forecasted Revenue of Sickle Cell Disease Drug (2021-2026)
20.3 Global Forecasted Price of Sickle Cell Disease Drug (2015-2026)
20.4 Global Forecasted Production of Sickle Cell Disease Drug by Region (2021-2026)
20.4.1 North America Sickle Cell Disease Drug Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Sickle Cell Disease Drug Production, Revenue Forecast (2021-2026)
20.4.3 Europe Sickle Cell Disease Drug Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Sickle Cell Disease Drug Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Sickle Cell Disease Drug Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Sickle Cell Disease Drug Production, Revenue Forecast (2021-2026)
20.4.7 Africa Sickle Cell Disease Drug Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Sickle Cell Disease Drug Production, Revenue Forecast (2021-2026)
20.4.9 South America Sickle Cell Disease Drug Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Sickle Cell Disease Drug Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Sickle Cell Disease Drug by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Sickle Cell Disease Drug by Country
21.2 East Asia Market Forecasted Consumption of Sickle Cell Disease Drug by Country
21.3 Europe Market Forecasted Consumption of Sickle Cell Disease Drug by Countriy
21.4 South Asia Forecasted Consumption of Sickle Cell Disease Drug by Country
21.5 Southeast Asia Forecasted Consumption of Sickle Cell Disease Drug by Country
21.6 Middle East Forecasted Consumption of Sickle Cell Disease Drug by Country
21.7 Africa Forecasted Consumption of Sickle Cell Disease Drug by Country
21.8 Oceania Forecasted Consumption of Sickle Cell Disease Drug by Country
21.9 South America Forecasted Consumption of Sickle Cell Disease Drug by Country
21.10 Rest of the world Forecasted Consumption of Sickle Cell Disease Drug by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer